达格列净联合美托洛尔缓释片治疗糖尿病合并心力衰竭的疗效分析

Efficacy Analysis of Dapagliflozin Combined with Metoprolol Extended release Tablets in the Treatment of Diabetes Mellitus Combined with Heart Failure

目的分析糖尿病合并心力衰竭患者采用达格列净联合美托洛尔缓释片治疗的效果。方法选取2021年1月—2023年10月靖江市第二人民医院收治的76例糖尿病合并心力衰竭患者为研究对象,根据随机数表法分为两组,各38例。对照组以美托洛尔缓释片治疗,研究组联合达格列净治疗,观察两组血糖、心功能及不良反应情况。结果治疗前,两组血糖指标相比,差异无统计学意义(P均>0.05)。治疗后,研究组空腹及餐后2 h血糖、糖化血红蛋白分别为(7.54±1.12)mmol/L、(10.01±2.52)mmol/L、(6.54±2.13)%,均低于对照组的(8.63±1.15)mmol/L、(12.82±4.15)mmol/L、(7.88±2.17)%,差异有统计学意义(t=4.186,3.568,2.717,P均<0.05)。治疗前,两组心功能对比,差异无统计学意义(P均>0.05)。治疗后,研究组心功能优于对照组,差异有统计学意义(P均<0.05);研究组不良反应发生率(10.53%)与对照组(5.26%)相比,差异无统计学意义(χ^(2)=0.181,P>0.05)。结论糖尿病合并心力衰竭采用达格列净联合美托洛尔治疗效果较好,不仅能稳定血糖,同时还能缓解心功能异常状态,且不良反应较少,安全性较高。

Objective To analyze the efficacy of diabetes mellitus combined with heart failure treated with dapa-gliflozin combined with metoprolol extended-release tablets.Methods A total of 76 patients with diabetes mellitus combined with heart failure in Jingjiang Second People's Hospital from January 2021 to October 2023 were selected as the study objects,and were divided into two groups of 38 patients each according to the randomized table method.The control group was treated with metoprolol extended-release tablets,and the study group was treated with com-bined dapagliflozin,and blood glucose,cardiac function and adverse reactions were observed in both groups.Results Before treatment,there was no statistically significant difference in blood glucose indexs between the two groups(all P>0.05).After treatment,the fasting plasma glucose,2-hour postprandial blood glucose and glycated hemoglobin of the study group were(7.54±1.12)mmol/L,(10.01±2.52)mmol/L,and(6.54±2.13)%,respectively,which were better than those of the control group(8.63±1.15)mmol/L,(12.82±4.15)mmol/L,and(7.88±2.17)%,and the differences were sig-nificantly significant(t=4.186,3.568,2.717,all P<0.05).Before treatment,there was no statistically significant differ-ence in cardiac function indexes between the two groups(all P>0.05).After treatment,the cardiac function indexes of the study group were better than those of the control group,and the differences were significantly significant(all P<0.05).The incidence of adverse reactions in the study group(10.53%)was higher than that in the control group(5.26%),and the difference was not significantly significant(χ^(2)=0.181,P>0.05).Conclusion Diabetes mellitus com-bined with heart failure is better treated with dapagliflozin combined with metoprolol,which not only stabilizes blood glucose,but also relieves the abnormal state of cardiac function,and has less adverse reactions and higher safety.